2[1]Chatenoud L,Herbelin A,Beaurain G,et al.Immune deficiency of the uremic patient.Adv Nephrol,1990,19:259
3[2]Manoussakis MN,Papadopoulos GK,Drosos AA,et al.Soluble interleukin-2 receptor moleucles in the serum of patients with autoimmune disease[J].Clin Immunol Immunopathol,1989,50(2):321
4[3]Wagner DK,Kiwanuka J,Edwards BK,et al.Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas:correlation with survival[J].J Clin Oncol,1987,5(2):1262
5[5]Cammusi G,Msriano F,Biancone L,et al.Effect of toskeleton of resident glomerular cells[J].Kidney Int,1993,43(suppl 39):32
6Mary E,Eberst MD,Lee R, et al .Hemostasis in renal diseases: Pathophysiology and Management[J]. Am J Med, 1994,96:168.
7Zachee P, Vermylen J. Boogaerts MA. Hematologic aspects of end-stage renal failure[J] .Ann Hematol, 1994,69:33.
8Vigano G,Benigni A,Mendogni D. Recombinant human ery thropoietin to correct uremic bleeding[J] .Am J kidney, 1991,18:44.
9Liani M, Salvati F, Tresca E, et al .Bleeding diathesis is uremic patients treated with peritoreal dialysis:role ofplatelet glycoproteins GP Ⅰ b and GP Ⅰ b/Ⅲ a abnormalities[J]. Nephron, 1996,74:234.
10Benigni A,Boccardo P, Galbusera M, et al .Reversible ac tivation defect of the platelet glycoprotein GP Ⅱ b- Ⅲ a a complex in patients with uremia[J] .Am J Kidney,1993,22(5):668.
